Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
Open Access
- 26 August 2022
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 196 (1) , 163-173
Abstract
Background: Black women in the USA have a higher incidence and mortality of metastatic breast cancer (mBC) than White women, while Hispanic women have lower rates. Previous studies have focused on first-line (1L) treatment, but little is known about racial differences in treatment beyond 1L and their impact on outcomes. Methods: This analysis utilized data from an electronic health record derived de-identified database and included patients with HR+HER2- mBC initiating 2L treatment (including CDK4/6-inhibitor [CDKi]-based, endocrine monotherapy, everolimus combination therapy, and chemotherapy and other systemic therapies) between 2/3/2015 and 7/31/2021. Real-world overall survival (rwOS) was defined as time from 2L initiation to death. Multinomial logistic regression assessed the likelihood of 2L treatment between race/ethnicity groups. Median rwOS was estimated using the Kaplan–Meier method and adjusted hazard ratios were estimated using multivariable Cox proportional hazards models. Results: Among all patients who received 2L, non-Hispanic Black (NHB) and Hispanic/Latino patients were less likely to receive 2L CDKi compared to non-Hispanic White (NHW) patients (36%, 39% vs 42%, respectively). Median rwOS was 20.4, 37.6, and 25.3 months, in NHB, Hispanic/Latino and NHW patients, respectively. The rwOS remained poorer among NHB patients after adjustment (HR = 1.16; p = 0.009). In stratified analysis, adjusted rwOS was similar between NHB and NHW patients among those who received 1L CDKi. Conclusions: These findings suggest that among patients with HR+HER2- mBC, NHB patients had worse survival beyond front-line setting, mainly among the subset of women who did not receive CDKi at 1L. This inequities in rwOS between race/ethnicity groups was not observed among patients who received 1L CDKi.Keywords
This publication has 27 references indexed in Scilit:
- Breast cancerThe Lancet, 2017
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology GuidelineJournal of Clinical Oncology, 2016
- Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry dataCancer Causes & Control, 2013
- Determinants of Breast Cancer Treatment Delay Differ for African American and White WomenCancer Epidemiology, Biomarkers & Prevention, 2013
- First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHERThe Oncologist, 2013
- Hispanic Mortality Paradox: A Systematic Review and Meta-Analysis of the Longitudinal LiteratureAmerican Journal of Public Health, 2013
- The influence of nativity and neighborhoods on breast cancer stage at diagnosis and survival among California Hispanic womenBMC Cancer, 2010
- Do healthy behaviors decline with greater acculturation?: Implications for the Latino mortality paradoxSocial Science & Medicine, 2005
- Socioeconomic status and breast cancer incidence in California for different race/ethnic groupsCancer Causes & Control, 2001
- The health of Hispanics in the southwestern United States: an epidemiologic paradox.1986